A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of Pf-06291874 Given As Monotherapy To Adults With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
Price : $35 *
At a glance
- Drugs PF 6291874 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 20 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 22 Dec 2014 Planned End Date changed from 1 Jan 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov record.